Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

JNJ

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

JNJ

AI Research Report

Powered by Claude

Ready to analyze JNJ

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Healthcare →
LLY
Eli Lilly
$810.50
+2.30%
UNH
UnitedHealth
$485.20
-2.51%
NVO
Novo Nordisk
—
—
TMO
Thermo Fisher
—
—
WELL
Welltower
—
—
ABBV
AbbVie
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Johnson & Johnson

Johnson & Johnson

Pharmaceuticals·NEW YORK STOCK EXCHANGE, INC.·US·IPO 1944-09-25

Analyst Consensus

Buy
Based on 32 analysts
Period: 2026-04-01
20 Buy (63%)12 Hold (38%)0 Sell (0%)
Rating Distribution
Strong Buy
6
Buy
14
Hold
12
Sell
0
Strong Sell
0
Trend
2026-04
20/12/0
2026-03
19/13/0
2026-02
19/13/0
2026-01
18/14/0
📅 Earnings today Before open
  • Yahoo·8h ago

    Dow Jones' J&J Slips Despite Beating First-Quarter Calls, Hiking Guidance

    Johnson & Johnson stock fell early Tuesday despite better-than-expected first-quarter sales and earnings, and a guidance boost.

  • Yahoo·9h ago

    Stocks Rise Pre-Bell Amid Hopes of Renewed US-Iran Peace Talks; Big Bank Earnings, PPI Data on Deck

    US equity futures were trending higher on Tuesday amid media reports that the US and Iran may revive

  • Yahoo·11h ago

    These Stocks Are Today’s Movers: Intel, American, Oracle, Novo Nordisk, Bloom Energy, Globalstar, JPMorgan, and More

    Stock futures were rising Tuesday as investors’ hopes for a peace deal between the U.S. and Iran strengthened. Intel climbed 1.4%, putting the chip maker on course to extend its winning streak to 10 sessions. Shares have jumped 58% over the past nine trading days, rallying thanks to collaborations with Tesla and Alphabet Google, and Intel buying back full control of its chip factory in Ireland.

  • Yahoo·9h ago

    Persian Gulf Outlook Undergirds Wall Street Pre-Bell; Asia, Europe Up

    Wall Street futures pointed moderately higher pre-bell Tuesday after President Donald Trump indicate

  • Yahoo·9h ago

    Johnson & Johnson raises 2026 outlook after strong Q1 earnings

    Strong demand for cancer drug Darzalex and psoriasis treatment Tremfya helped offset a steep drop in Stelara sales

  • Yahoo·9h ago

    Johnson & Johnson (JNJ) Surpasses Q1 Earnings and Revenue Estimates

    Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +1.07% and +2.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

  • Yahoo·10h ago

    Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter.

    Johnson & Johnson has reinvented itself several times in recent years. J&J posted adjusted earnings of $2.70 a share for the first quarter, narrowly beating out the $2.68 a share analysts had anticipated. Sales grew by more than 11% in J&J’s Innovative Medicine arm, which includes its oncology portfolio, and 7.7% in its medical technology division.

  • SeekingAlpha·10h ago

    Wall Street Lunch: Big Banks Open Earnigs Season With Mixed Results

    Earnings season kicked off in earnest with mixed results from the big banks.

  • View all news →
NEW YORK STOCK EXCHANGE, INC.After-hours
Johnson & Johnson
Pharmaceuticals
$240.43
$2.47 (+1.04%)
After-hrs · vs prev close $237.96
Open
$236.44
Prev close
$237.96
Day range
$233.25 – $241.66
52W range
$145.13 – $251.71
Mkt cap
$573.15B
P/E
21.2
EPS
$11.05
Beta
0.32

Fundamentals

Valuation
Market Cap
$573.15B
P/E (TTM)
21.20S&P avg ~22
P/S (TTM)
6.03S&P avg ~2.8
P/B
6.13S&P avg ~4.5
P/FCF
28.85S&P avg ~26
EPS (TTM)
$11.05
Book/sh
$33.86
Cash/sh
$8.35
Profitability
Gross Margin
67.92%avg ~45%
Operating Margin
34.59%avg ~15%
Net Margin
28.46%avg ~12%
ROE
33.78%avg ~18%
ROA
13.76%avg ~7%
ROI
20.85%
Payout Ratio
46.19%
FCF/sh
—
Growth & Health
Rev Growth YoY
6.05%
Rev Growth 5Y
2.67%
EPS Growth YoY
90.56%
EPS Growth 5Y
14.90%
Current Ratio
—
Quick Ratio
0.69
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.32
52W High
$251.71
52W Low
$145.13
Avg Vol (10D)
6.87M
Avg Vol (3M)
8.50M
Div Yield
2.19%
Div/sh (TTM)
—
Analyst
Buy (32)
Price Performance
5D-0.19%
MTD-2.65%
3M+15.65%
6M+26.47%
YTD+14.98%
1Y+60.04%

Factor Grades

View details →
B
Overall score: 68/100
C
Valuation
B-
Growth
A
Profitability
B+
Momentum
B-
Financial Health
⚠️
Dilution risk detected

1 offering-related filing in the last 60 filings. Latest: S-3ASR on 2026-02-11. View all →

Recent insider activity

View all →
  • 4FORM 4
    Mar 12
  • 4FORM 4
    Mar 12
  • 4FORM 4
    Mar 12
  • 4FORM 4
    Mar 3
  • 4FORM 4
    Feb 23